Section of Oncology
1 di 6
[ Meet the Professor ]
10th Meet The Professor
Advanced International Breast Cancer Course
(AIB...
Section of Oncology
2 di 6
[ Preliminary Program]
Thursday, November 6th
8.00 Registration
8.45 Introduction to the Confer...
Section of Oncology
3 di 6
14.30 Is there a role for adjuvant bisphosphonates?
Robert Coleman
SESSION V
GUIDELINES
15.00 R...
Section of Oncology
4 di 6
16.00 Coffee break
16.30 Clinical case discussion IV
1 presenter and 1 discussant each (with te...
Section of Oncology
5 di 6
and advanced disease, strategies to overcome resistance to available therapies, innovative ther...
Section of Oncology
6 di 6
Sibylle Loibl
German Breast Group
Department of Medicine and Reasearch
University of Frankfurt ...
Upcoming SlideShare
Loading in …5
×

10th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC),

305 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
305
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

10th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC),

  1. 1. Section of Oncology 1 di 6 [ Meet the Professor ] 10th Meet The Professor Advanced International Breast Cancer Course (AIBCC) Padua, November 6-8, 2014 The Conference will include: 1) Lectures: Internationally recognized speakers provide a balanced overview of selected topics 2) Clinical Case Discussions: Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced breast cancer will be presented. All participants will be requested to express their vote among a predefined list of options. Expert panelists will then provide their opinion and discuss the audience choices. 3) Highlights: Internationally recognized speakers give an update of significant advances presented at major meetings (ASCO, ESMO, SABCS) on preselected topics
  2. 2. Section of Oncology 2 di 6 [ Preliminary Program] Thursday, November 6th 8.00 Registration 8.45 Introduction to the Conference Pier Franco Conte, Gabriel N. Hortobagyi SESSION I PATHOLOGY 9.00 Standardization of breast cancer diagnosis: pathology Giuseppe Viale 9.30 Standardization of breast cancer diagnosis: genomics Giampaolo Bianchini SESSION II LOCO-REGIONAL THERAPIES 10.00 Evolving loco-regional management  Do margins still matter - Alberto Costa  Sentinel node biopsy and axillary node dissection: does radiotherapy matter? – TBD  Hypofractionated breast irradiation- Philip Poortmans 11.00 Coffee break SESSION III IMAGING 11.30 MRI in breast cancer diagnosis 3 clinical cases will be presented by a young doctor (local faculty). The following items will be discussed: - Is MRI the standard screening procedure in young women? - Is MRI the gold standard to assess the response to neoadjuvant therapy? - Is MRI appropriate to plan type of surgery? The audience will be asked to vote. After the vote, two senior speakers (TBD) will discuss items in favor or contra. The audience will be asked to vote again after the discussion. 13.00 Lunch SESSION IV STAGING AND ADJUVANT 14.00 Appropriate work out staging in early breast cancer TBD
  3. 3. Section of Oncology 3 di 6 14.30 Is there a role for adjuvant bisphosphonates? Robert Coleman SESSION V GUIDELINES 15.00 Role of guidelines in the era of personalized cancer medicine - do guidelines impact on patients outcome? TBD - how to reconcile the increasing complexity of breast tumors in simple guidelines TBD 16.30 Adjourn 17.30 Ceremony for the presentation of the University of Padua Award for Advances Breast Cancer 2014 and the Monica Boscolo Research Grant 18.00 Lecture of the Awardee 18.30 Adjourn Friday, November 7th SESSION VI EARLY BREAST CANCER 9.00 Adjuvant – Clinical Case Discussion I 1 presenter and 1 discussant each (with tele voting) - Fertility preservation. Presenter: local faculty. Discussant: TBD - Adjuvant therapy for low risk HER2+ patients. Presenter: local faculty. Discussant: TBD - Adjuvant chemotherapy for HR? Presenter: local faculty. Discussant: TBD 11.00 Coffee break 11.30 Neoadjuvant – Clinical Case Discussion II 1 presenter and 1 discussant each (with tele voting) - HR+/HER2 negative. Presenter: local faculty. Discussant: TBD - Adjuvant therapy in suboptimal responders after neoadjuvant therapy. Presenter: local faculty. Discussant: TBD - Triple negative breast cancer (platinum salts, BRCA testing). Presenter: local faculty. Discussant: TBD 13.30 Lunch SESSION VII ADVANCED BREAST CANCER 14.30 Clinical case discussion III 1 presenter and 1 discussant each (with tele voting) - Sequence and duration of anti-HER2 therapy. Presenter: local faculty. Discussant: TBD - New landscape of treatment for HR+ disease. Presenter: local faculty. Discussant: TBD - Triple negative advanced breast cancer. Presenter: local faculty. Discussant: TBD
  4. 4. Section of Oncology 4 di 6 16.00 Coffee break 16.30 Clinical case discussion IV 1 presenter and 1 discussant each (with tele voting) - Loco-regional treatments for CNS metastases. Presenter: local faculty. Discussant: TBD - Surgery of the primary in de novo stage IV disease. Presenter: local faculty. Discussant: TBD 18.00 Adjourn Saturday, November 8th SESSION VIII HIGHLIGHTS OF THE YEAR 9.00 Advances in biology TBD 9.30 HER2+ early and advanced disease TBD 10.00 HR+/HER2- early and advanced disease TBD 10.30 Triple negative early and advanced disease TBD 11.00 Coffee break SESSION IX COMING SOON 11.30 New promising drugs TBD 12.00 Trials likely to impact on clinical practice in the near future: EBC TBD 12.30 Trials likely to impact on clinical practice in the near future: ABC TBD 13.00 Adjourn and final evaluation questionnaire [ Aims] Breast cancer mortality is declining in most countries as a result of advances in the knowledge of the mechanisms of cancer progression, phenotypic and genotypic characterization of the disease, screening programs, advanced imaging, local therapies and molecularly targeted drugs. Nowadays, breast cancer represents the front runner in the path to comparative effectiveness where new therapeutic interventions are implemented on the basis of “average” benefit to personalized cancer medicine where the right treatment is provided to the right patient at the right moment. An updated, multifaceted approach to our patients is now becoming more and more demanding and with these goals in mind, the Programme of this international Conference includes lectures on the molecular characterization, updated management of early
  5. 5. Section of Oncology 5 di 6 and advanced disease, strategies to overcome resistance to available therapies, innovative therapies, and multimodal treatments for advanced disease. Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants. This 10th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances. In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 10th AIBCC will award the 4th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year and the Monica Boscolo Research Grant to an Italian scientist for a research project to be conducted in cooperation with a foreign institution. We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere. [ Addressed to] Oncologists, biologists, pathologists, radiologists, radiation oncologists, surgeons, gynaecologists, biologists and nurses. [ Directors ] Pier Franco Conte Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Gabriel N. Hortobagyi Department of Breast Medical Oncology University of Texas - MD Anderson Cancer Center Houston (USA) [ Scientific Committee] Jonas Bergh Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW) Valentina Guarneri Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I) Jacek Jassem Department of Oncology and Radiotherapy Medical University of Gdansk (PL) Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)
  6. 6. Section of Oncology 6 di 6 Sibylle Loibl German Breast Group Department of Medicine and Reasearch University of Frankfurt (D) Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Maranon Madrid (S) Donato Nitti Department of Surgery, Oncology and Gastroenterology University of Padua (I) Philip Poortmans President-elect of ESTRO Department of Radiation Oncology Dr. Verbeeten Instituut Tilburg (NL) [ Meeting Venue] Centro Congressi Padova “A. Luciani” Via Forcellini, 170/A Padova tel. 049/8033711

×